Kopaq (Iohexol)

Iohexol is a non‑ionic, iodine‑rich compound. When injected, its high‑density iodine atoms absorb X‑ray photons, increasing the attenuation of the X‑ray beam in the area where it circulates. This creates a contrast between the enhanced structures and surrounding tissues, allowing better image definition.

The dose of Kopaq is determined by the prescribing physician based on the specific imaging study, patient size, renal function, and the route of administration. Healthcare professionals calculate the appropriate volume and concentration required for each procedure.

Safety of iohexol in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kopaq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kopaq (iohexol) is a non‑ionic, low‑osmolality contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other non‑ionic agents such as iopamidol, iohexol provides similar image quality and is often chosen based on availability, cost, and specific institutional preferences.

Kopaq should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Do not freeze. Before use, inspect the vial for particulate matter or discoloration and handle with aseptic technique.

Kopaq is administered by a qualified healthcare professional via intra‑arterial, intravenous, or intrathecal injection, depending on the imaging study. The injection rate and volume are controlled to achieve optimal contrast enhancement while minimizing adverse reactions.

The most serious risks include severe allergic reactions (anaphylaxis), contrast‑induced nephropathy leading to acute kidney injury, and cardiac arrhythmias that may occur with rapid injection. Immediate medical attention is required if any of these events are suspected.

Kopaq should be avoided in patients with a known hypersensitivity to iodine‑based contrast media, severe renal impairment, uncontrolled hyperthyroidism, or those who have experienced severe reactions to previous contrast agents. The prescribing clinician must assess each patient’s suitability before use.